Efficient scavenger receptor-mediated hepatic targeting of proteins by introduction of negative charges on the proteins by aconitylation: the influence of charge density and size of the proteins molecules.
The in vivo disposition characteristics of some aconitylated proteins in mice were studied after intravenous injection in relation to their molecular properties such as overall negative charge and size of the molecules. Superoxide dismutase (SOD, M(w)=32000) and bovine serum albumin (BSA, M(w)=67000) were used to produce aconitylated derivatives with a different extent of modification. Aconitylated SOD (Aco-SOD) was only moderately taken up by the liver in spite of its negative charge density, whereas aconitylated BSA (Aco-BSA) with a smaller charge density was taken up by the liver very efficiently. Aco-BSA was more rapidly cleared by the liver than succinylated BSA due to the introduction of more anionic groups, especially when the degree of modification was low. Interestingly, highly aconitylated BSAs exhibited significant accumulation in the kidney at higher doses, especially when the hepatic uptake was saturated. Further analysis that was based on a physiological pharmacokinetic model including a saturable hepatic uptake process revealed that the higher the number of negative charges on the proteins, the higher was the apparent affinity of aconitylated proteins for the hepatic SRs. In general, the affinity of aconitylated proteins was higher than that of succinylated proteins when the degree of acylation was the same. Thus, the present study indicates that apart from charge density on the proteins the molecular size of the proteins is important for SR-mediated uptake in the liver. Aconitylation of proteins seems more suitable than succinylation for targeting of proteins to the liver nonparenchymal cells, in particular, at a low degree of acylation of the proteins at which the enzymatic activity is better retained for sufficient negative charges introduced.
Yamasaki
Yasuomi
Y
Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
Hisazumi
Jin
J
Yamaoka
Kiyoshi
K
Takakura
Yoshinobu
Y
D000156:Aconitic Acid / Q000737:chemistry / Q000493:pharmacokinetics; D000818:Animals; D019540:Area Under Curve; D016166:Free Radical Scavengers / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008297:Male; D008565:Membrane Proteins; D008657:Metabolic Clearance Rate; D051379:Mice; D011485:Protein Binding; D011869:Radioligand Assay; D011971:Receptors, Immunologic / Q000378:metabolism*; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; D051122:Scavenger Receptors, Class B; D012588:Scintillation Counting; D012710:Serum Albumin, Bovine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013386:Succinates / Q000737:chemistry; D013482:Superoxide Dismutase / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014018:Tissue Distribution
D016166:Free Radical Scavengers; D008565:Membrane Proteins; D011971:Receptors, Immunologic; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; C454739:Scarb1 protein, mouse; D051122:Scavenger Receptors, Class B; D013386:Succinates; D012710:Serum Albumin, Bovine; D000156:Aconitic Acid; D013482:Superoxide Dismutase